Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy

Value in Health

Volumn 14, Issue 1, 2011, Pages 80-89

  Iannazzo, S ^a   Pradelli, L ^a   Carsi, M ^a   Perachino, M ^b  

^a AdRes Health Economics and Outcomes Research   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Cost effectiveness; Hormone therapy; Prostate cancer; Testosterone

Indexed keywords

BUSERELIN; GOSERELIN; LEUPRORELIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TESTOSTERONE; TRIPTORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SIMULATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION TREE; DRUG COST; ECONOMICS; META ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; STATISTICAL MODEL; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BUSERELIN; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; ITALY; LEUPROLIDE; MALE; MODELS, ECONOMETRIC; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TRIPTORELIN;

EID: 79952680780     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.023     Document Type: Article

References (45)

1. Grande E, Inghelmann R, Francisci S, et al. Regional estimates of all cancer malignancies in Italy. Tumori 2007;93:345-51. (Pubitemid 47403449)
2. Inghelmann R, Grande E, Francisci S, et al. Regional estimates of prostate cancer burden in Italy. Tumori 2007;93:380-6. (Pubitemid 47403454)
3. Fourcade RO, Benedict A, Black LK, et al. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int 2010;105:49-56.
4. AURO.it (Associazione Urologi Italiani-Association of Italian Urologists) AUROLINE 10: Guidelines on prostate cancer: diagnosis, staging and therapy, 2008. Available from: http://www.auro.it/wp-content/uploads/al10.pdf [Accessed May 4, 2010].
5. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010;105:648-51.
6. Novara G, Galfano A, Secco S, et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol Int 2009, 82:249-55.
7. De Jong IJ, Eaton A, Bladou F. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion. Curr Med Res Opin 2007;23:1077-80. (Pubitemid 46799591)
8. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice of decision analytic modeling in health care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
9. ISTAT (Italian National Institute of Statistics) Table 2.16: Mortality Table by Age and Sex, 2005. Annuario Statistico Italiano, ISTAT, 2008.
10. Waxman J, Sandow J, Abel P, et al. Three-monthly GnRH agonist (buserelin) for prostatic cancer. Br J Urol 1990, 65:43-5. (Pubitemid 20053953)
11. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-8.
12. Fernandez del Moral P, Dijkman GA, Debruyne FM, et al. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology 1996;48:894-900.
13. Debruyne FM, Dijkman GA, Lee DC, et al. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. J Urol 1996;155:1352-4. (Pubitemid 26081237)
14. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160:1685-8. (Pubitemid 128746738)
15. Oefelein MG: Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999;54:694-9. (Pubitemid 29449432)
16. Sarosdy MF, Schellhammer PF, Soloway MS, et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83:801-06. (Pubitemid 29224400)
17. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164:726-9. (Pubitemid 30637611)
18. Fowler JE, Flanagan M, Gleason DM, et al. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 2000;55:639-42.
19. Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199-203.
20. Perez-Marreno R, Chu FM, Gleason D, et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902-14. (Pubitemid 35440958)
21. Fontana D, Mari M, Martinelli A, et al. 3-month formulation of goserelin acetate ("Zoladex" 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 2003;70:316-20. (Pubitemid 36566264)
22. Sartor O, Dineen MK, Perez-Marreno R, et al. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003;62:319-23. (Pubitemid 36952085)
23. Heyns CF, Simonin M, Grosgurin P, et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92:226-31. (Pubitemid 36966582)
24. Teillac P, Heyns CF, Kaisary AV, et al. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res 2004;62:252-8. (Pubitemid 39551740)
25. Chander S, Choo R, Danjoux C, et al. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 2005;62:719-24. (Pubitemid 40779760)
26. Pettersson B, Varenhorst E, Petas A, Sandow J. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate: a 12-month follow-up study. Eur Urol 2006;50:483-9. (Pubitemid 44189052)
27. Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533-6. (Pubitemid 43067346)
28. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-8. (Pubitemid 41789955)
29. Fujii Y, Yonese J, Kawakami S, et al. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU Int 2008;101:1096-100. (Pubitemid 351502651)
30. Italian Drug Formulary: L'Informatore Farmaceutico, 69th ed. Italy: Elsevier Masson, 2009.
31. Italian Specialist Tariffs: Nomenclatore Tariffario Nazionale, D. M. 22, July 1996.
32. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
33. Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J 2001;35:189-201. (Pubitemid 32198569)
34. Guide to Cost-Benefit Analysis of Investment Projects. Evaluation Unit, DG Regional Policy, European Commission, 2002.
35. Italian Health Economics Association (AIES). A proposal for guidelines for the economic evaluation of health interventions in Italy. PharmacoEconomics Italian Research Articles 2009;11:83-93.
36. Evans D. Social discount rate for the European Union: new estimates. In: Florio M, ed. Cost-Benefit Analysis and Incentives in Evaluation: The Structural Funds of the European Union. Edward Elgar Publishing, 2007.
37. Istituto Nazionale per l'Impatto Sociale dell'Economia (INISE). L'analisi costi-benefici. Available from: http://www.bilanciosociale.info/public/ documenti/Libro/capitolo%204.doc [Accessed May 2010].
38. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
39. Tosteson AN. Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine 1997;22(24 Suppl.):58S-62S. (Pubitemid 28123773)
40. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765-7. (Pubitemid 36336720)
41. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300-3. (Pubitemid 33135166)
42. Towse A, Raftery J. Should NICE's threshold range for cost per QALY be raised? BMJ 2009;338:268-9.
43. World Health Organization. Commission on Macroeconomics and Health Report. Macroeconomics and Health: Investing in Health for Economic Development. Geneva, 2001. Available from: http://whqlibdoc.who.int/publications/2001/ 924154550x.pdf [Accessed November 2010].
44. ISTAT (Italian National Institute of Statistics) Historical Series of Per Capita Gross Domestic Product (GDP) (1970-2007). Available from: http://www.istat.it/conti/[Accessed March 2010].
45. Agenzia Nazionale per i Servizi Sanitari Regionali. Tariffe delle prestazioni specialistiche ambulatoriali aggiornato al 31 dicembre 2008. Nomenclatore delle Prestazioni specialistiche ambulatoriali-confronto tra le tariffe nazionali ex DM 1996 e le tariffe regionali relative all'anno 2008. Available from: http://www.agenas.it/[Accessed February 2010].